| 1 |
20065114 | NCX 4040, a nitric oxide-donating aspirin, exerts anti-inflammatory effects through inhibition of I kappa B-alpha degradation in human monocytes. | 2010 Feb 15 |
1 |
| 2 |
20299485 | Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. | 2010 Jun |
2 |
| 3 |
20608787 | Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia. | 2010 |
1 |
| 4 |
19341823 | Comparative effects of aspirin and NO-releasing aspirins on differentiation, maturation and function of human monocyte-derived dendritic cells in vitro. | 2009 Jul |
6 |
| 5 |
18196976 | NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. | 2008 Jan 1 |
2 |
| 6 |
18302761 | NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols. | 2008 Feb 26 |
1 |
| 7 |
18472019 | NCX 4040, an NO-donating acetylsalicylic acid derivative: efficacy and mechanisms of action in cancer cells. | 2008 Sep |
2 |
| 8 |
18485921 | Nitrates and NO-NSAIDs in cancer chemoprevention and therapy: in vitro evidence querying the NO donor functionality. | 2008 Sep |
2 |
| 9 |
18492771 | The nitric oxide-donating derivative of acetylsalicylic acid, NCX 4016, stimulates glucose transport and glucose transporters translocation in 3T3-L1 adipocytes. | 2008 Jul |
2 |
| 10 |
17334512 | Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. | 2007 Mar |
1 |
| 11 |
17760507 | Nitroaspirin (NCX-4016), an NO donor, is antiangiogenic through induction of loss of redox-dependent viability and cytoskeletal reorganization in endothelial cells. | 2007 Nov |
1 |
| 12 |
17903525 | Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein-carotid artery interposition grafting: a comparison with aspirin and morpholinosydnonimine (SIN-1). | 2007 Oct |
4 |
| 13 |
17971198 | Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines. | 2007 Oct 30 |
2 |
| 14 |
16497833 | Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. | 2006 Mar 7 |
2 |
| 15 |
16961726 | Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. | 2006 Summer |
3 |
| 16 |
16144976 | Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). | 2005 Dec |
5 |
| 17 |
14563672 | Antioxidant activity of nitro derivative of aspirin against ischemia-reperfusion in hamster cheek pouch microcirculation. | 2004 Mar |
2 |
| 18 |
14762100 | Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence. | 2004 Jun |
5 |
| 19 |
14762891 | Polymorphism of NCX4016, an NO-releasing derivative of acetylsalicylic acid. | 2004 Mar |
1 |
| 20 |
15240674 | Nitric oxide regulates immune cell bioenergetic: a mechanism to understand immunomodulatory functions of nitric oxide-releasing anti-inflammatory drugs. | 2004 Jul 15 |
4 |
| 21 |
15358033 | Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. | 2004 Aug 4 |
3 |
| 22 |
12612897 | Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. | 2003 Mar |
2 |
| 23 |
12738997 | NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. | 2003 Jun |
3 |
| 24 |
12846439 | NO-aspirin: mechanism of action and gastrointestinal safety. | 2003 May |
5 |
| 25 |
12960371 | Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. | 2003 Sep 16 |
2 |
| 26 |
14582459 | NCX-4016 NicOx. | 2003 Sep |
1 |
| 27 |
12207011 | NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function. | 2002 Oct |
1 |
| 28 |
11447266 | NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. | 2001 Jul 17 |
1 |
| 29 |
10968413 | The effect of aspirin and two nitric oxide donors on the infarcted heart in situ. | 2000 Jul 7 |
1 |
| 30 |
11046058 | IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. | 2000 Nov 1 |
1 |
| 31 |
10065898 | In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016. | 1999 Jan 1 |
1 |
| 32 |
9435549 | Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: role of neutrophils. | 1997 Dec |
1 |
| 33 |
8735820 | In vitro study of the anti-aggregating activity of two nitroderivatives of acetylsalicylic acid. | 1996 Mar |
3 |
| 34 |
8950792 | The antiplatelet effects of a new nitroderivative of acetylsalicylic acid--an in vitro study of inhibition on the early phase of platelet activation and on TXA2 production. | 1996 Nov |
1 |